Brief: D&D Pharmatech's DD01 Cuts Liver Fat, Boosts Liver & Metabolic Health in Phase 2 MASH Trial
16/06/2025 11:03
June 16 (Reuters) - DND Pharmatech Inc 347850.KQ: D&D PHARMATECH ANNOUNCES POSITIVE PHASE 2 RESULTS FOR DD01 IN MASH WITH ROBUST REDUCTIONS IN LIVER FAT ACCOMPANIED BY IMPROVEMENTS IN LIVER AND METABOLIC HEALTH D&D PHARMATECH ANNOUNCES POSITIVE PHASE 2 RESULTS FOR DD01 IN MASH WITH ROBUST REDUCTIONS IN LIVER FAT ACCOMPANIED BY IMPROVEMENTS IN LIVER AND METABOLIC HEALTH DND PHARMATECH INC - 75.8% OF DD01-TREATED SUBJECTS ACHIEVED AT LEAST 30% REDUCTION IN LIVER FAT DND PHARMATECH INC - DD01 TREATMENT ASSOCIATED WITH 62.3% RELATIVE REDUCTION IN LIVER FAT DND PHARMATECH INC - DD01 WELL TOLERATED WITH MILD TO MODERATE GI SIDE EFFECTS DND PHARMATECH INC - DD01 TREATMENT RESULTED IN SIGNIFICANT REDUCTIONS IN HBA1C AND BODY WEIGHT DND PHARMATECH INC - ONLY 3 SUBJECTS DISCONTINUED DD01 TREATMENT DUE TO GI SIDE EFFECTS Source text: ID:nBw8Yzhkya Further company coverage: 347850.KQ ((Reuters.Briefs@thomsonreuters.com;))